Department of General Surgery, General Hospital of PLA Beijing Military Command, Beijing 100700, China.
World J Gastroenterol. 2013 Jun 28;19(24):3841-6. doi: 10.3748/wjg.v19.i24.3841.
To investigate the safety and efficacy of anus-preserving rectectomy via telescopic colorectal mucosal anastomosis (TCMA) for low rectal cancer.
From August 1993 to October 2012, 420 patients including 253 males and 167 females with low rectal cancer underwent transabdominal and transanal anterior resection, followed by TCMA. The distance between the anus and inferior margin of the tumor ranged from 5 to 7 cm, and was 5 cm in 6 patients, 6 cm in 127, and 7 cm in 287 patients. Tumor-node-metastasis staging showed that 136 patients had stage I, 252 had stage II and 32 had stage III. Fifty-six patients with T3 or over received preoperative neoadjuvant chemoradiotherapy.
The postoperative follow-up rate was 91.9% (386/420) with a median time of 6.4 years. All 420 patients underwent radical resection. No postoperative death occurred. Postoperative complications included anastomotic leakage in 13 (3.1%) patients and anastomotic stenosis in 7 (1.6%). The local recurrence rate after surgery was 6.2%, the hepatic metastasis rate was 13.2% and the pulmonary metastasis rate was 2.3%. The 5-year survival rate was 74.0% and the disease-free survival rate was 71.0%. Kirwan classification showed that continence was good in 94.4% of patients with stage I when scored 12 mo after resection.
TCMA for patients with low rectal cancer leads to better quality of life and satisfactory defecation function, and lowers anastomotic leakage occurrence, and might be one of the safe operative procedures in anus-preserving rectectomy.
探讨经直肠黏膜吻合器(TCMA)行肛门直肠保肛切除术治疗低位直肠癌的安全性和有效性。
1993 年 8 月至 2012 年 10 月,420 例低位直肠癌患者(男 253 例,女 167 例)接受经腹经肛门前切除术,然后行 TCMA。肛门与肿瘤下缘的距离为 5~7cm,其中 6cm 6 例,6cm 127 例,7cm 287 例。肿瘤-淋巴结-转移分期显示,Ⅰ期 136 例,Ⅱ期 252 例,Ⅲ期 32 例。56 例 T3 及以上患者接受术前新辅助放化疗。
术后随访率为 91.9%(386/420),中位随访时间为 6.4 年。420 例患者均行根治性切除术,无术后死亡。术后并发症包括吻合口漏 13 例(3.1%)和吻合口狭窄 7 例(1.6%)。术后局部复发率为 6.2%,肝转移率为 13.2%,肺转移率为 2.3%。5 年生存率为 74.0%,无病生存率为 71.0%。Kirwan 分级显示,术后 12 个月,Ⅰ期患者的肛门功能评分为 12 分,其中 94.4%的患者肛门功能良好。
TCMA 治疗低位直肠癌可提高患者的生活质量和排便功能,降低吻合口漏的发生率,可能是保肛直肠切除术的一种安全术式。